Stephen Kent Webb Od Optometrist Medicare: Not Enrolled in Medicare Practice Location: 601 W 7th St, Plainview, TX 79072 Phone: 806-293-1376 Fax: 806-291-8700 |
Dr. Tobin Neil Holloway, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1501 N I-27, Plainview, TX 79072 Phone: 806-288-0400 Fax: 806-288-0401 |
Luke Sherman, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1501 N I27, Plainview, TX 79072 Phone: 806-463-8243 |
Dr. Stephen Kent Webb, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 601 W 7th St, Plainview, TX 79072 Phone: 806-293-1376 Fax: 806-291-8700 |
Dr. Joseph Stewart Webb, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 601 W 7th St, Plainview, TX 79072 Phone: 806-293-1376 Fax: 806-291-8700 |
Tobin Holloway, O.d., P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1501 N I-27, Plainview, TX 79072 Phone: 806-288-0400 Fax: 806-288-0401 |
Dr. Lindsie Marie Mathis, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 601 W 7th, Plainview, TX 79072 Phone: 806-293-1376 Fax: 806-291-8700 |
News Archive
"For a country that has a large population of heavy smokers, the Italian Government has shown real courage in the fight against passive smoking," said association President Dr Paul Skerritt.
Takeda Pharmaceuticals International GmbH today announced the presentation of data further demonstrating the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
The Washington Post: "According to experts and industry insiders, recent trends suggest [health insurance] rates will continue to rise and employers will continue to shift more of the cost of health insurance onto workers - asking them to shoulder a larger share of premiums, for instance, or increasing out-of-pocket costs such as deductibles and co-pays."
Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States.
› Verified 8 days ago